bovin
respiratori
diseas
brd
lead
caus
morbid
mortal
product
class
cattl
calv
us
caus
loss
cattl
industri
excess
billion
dollar
annual
multipl
etiolog
includ
viral
bacteri
contribut
brd
gener
accept
import
contributor
brd
includ
viral
pathogen
bovin
bovin
viral
diarrhea
viru
type
bvdv
bovin
respiratori
syncyti
viru
brsv
viru
bacteria
mannheimia
haemolytica
pasteurella
multocida
histophilu
somni
mycoplasma
bovi
brd
frequent
initi
viral
infect
disrupt
local
defens
andor
caus
immun
suppress
allow
opportunist
bacteri
pathogen
healthi
anim
normal
nasophayng
commens
prolifer
infect
lung
superimpos
environment
manag
relat
stress
advers
weather
ship
commingl
suppress
host
immun
system
increas
pathogen
exposur
may
import
corequisit
mani
brd
outbreak
although
vaccin
antibiot
treatment
readili
avail
prevent
treat
infect
caus
common
brd
pathogen
incid
diseas
remain
high
recent
year
bovin
coronaviru
bcv
implic
import
contributor
brd
although
initi
describ
associ
calf
diarrhea
bcv
found
infect
upper
lower
respiratori
tract
isol
pneumon
lung
alon
combin
respiratori
pathogen
addit
result
multipl
studi
indic
group
cattl
high
titer
serum
antibodi
bcv
time
feedlot
entri
less
like
shed
bcv
develop
brd
low
antibcv
serum
antibodi
titer
taken
togeth
appear
bcv
contribut
feedlot
brd
high
titer
serum
antibcv
antibodi
associ
reduc
risk
bcv
infect
diseas
howev
remain
unknown
whether
serum
antibodi
immun
correl
protect
whether
simpli
reflect
prior
exposur
viru
relationship
bcv
brd
prewean
beef
calv
comprehens
evalu
though
bcv
frequent
detect
nasal
swab
nurs
calv
brd
subclin
bcv
infect
also
common
young
dairi
calv
even
presenc
rel
high
antibcv
antibodi
titer
result
rais
question
associ
antibcv
antibodi
titer
bcv
shed
risk
develop
brd
nurs
dairi
calv
similarli
studi
group
sampl
four
research
herd
n
predefin
time
birth
fifth
week
feedlot
studi
reveal
herd
bcv
detect
nasal
section
prewean
period
also
highest
incid
prewean
brd
howev
nasal
swab
collect
time
treatment
diagnos
pathogen
associ
prewean
brd
case
studi
also
report
serum
antibcv
antibodi
abund
correl
bcv
shed
prior
wean
thu
mount
evid
suggest
antibcv
antibodi
protect
wean
feedlot
cattl
brd
associ
bcv
infect
relationship
humor
immun
bcv
viru
shed
risk
develop
brd
nurs
calv
remain
unclear
repres
major
obstacl
develop
effect
control
strategi
reduc
impact
bcvrelat
respiratori
diseas
cattl
signific
given
current
licens
bcv
vaccin
unit
state
aid
prevent
brd
address
knowledg
gap
present
studi
serial
sampl
calv
three
herd
beef
cattl
birth
wean
determin
whether
shed
bcv
associ
brd
whether
level
antibcv
serum
antibodi
associ
bcv
shed
brd
incid
prewean
beef
calv
sequenc
analysi
viru
strain
circul
herd
preval
common
opportunist
bacteri
pathogen
haemolytica
p
multocida
h
somni
mycoplasma
bovi
upper
respiratori
tract
sick
appar
healthi
cattl
also
evalu
account
potenti
confound
factor
could
influenc
brd
develop
popul
experiment
procedur
perform
approv
guidelin
us
meat
anim
research
center
usmarc
institut
anim
care
use
committe
iacuc
approv
number
eight
hundr
seventeen
naturalservic
crossbr
beef
calv
born
march
may
follow
birth
wean
fig
calv
part
ongo
germplasm
evalu
program
usmarc
locat
approxim
acr
near
clay
center
nebraska
usa
calv
product
multiplesir
mate
crossbr
cow
bull
vari
breed
composit
result
calv
use
within
studi
consist
variabl
fraction
breed
angu
hereford
red
angu
brahman
charolai
gelbvieh
limousin
simment
brangu
beefmast
shorthorn
main
anjou
santa
gertrudi
chiangu
saler
braunvieh
south
devon
tarentais
studi
calv
origin
three
research
herd
manag
separ
locat
usmarc
three
herd
fencelin
contact
direct
pathogen
transmiss
herd
calv
rais
similar
manag
receiv
standard
vaccin
describ
herd
characterist
includ
number
calv
enrol
studi
herd
median
dam
pariti
within
herd
mean
standard
deviat
wean
age
weight
studi
calv
summar
tabl
three
herd
contain
calv
addit
target
popul
enrol
studi
herd
consist
calv
born
result
artifici
insemin
natur
servic
wherea
herd
consist
calv
born
result
fullseason
natur
servic
breed
natur
servic
calv
herd
enrol
studi
calv
born
result
artifici
insemin
enrol
anoth
studi
center
result
differ
mean
age
weight
studi
calv
wean
tabl
addit
calv
herd
manag
ident
target
popul
sampl
studi
dam
dam
three
herd
receiv
modifi
live
viru
mlv
vaccinebacterin
combin
product
bovishield
gold
fp
vl
zoeti
florham
park
nj
contain
mlv
strain
bvdv
type
brsv
inactiv
suspens
campylobact
fetu
strain
leptospira
vaccin
given
annual
prior
breed
approxim
june
one
three
week
breed
dam
also
vaccin
enter
pathogen
approxim
day
begin
calv
season
vaccin
scourguard
zoeti
contain
kill
strain
bovin
rotaviru
bcv
escherichia
coli
bacterin
clostridium
perfringen
type
c
toxoid
vaccin
enhanc
product
secret
antibodi
pathogen
colostrum
aid
prevent
diarrhea
calv
bcv
contain
vaccin
use
studi
calv
timelin
calf
vaccin
provid
fig
approxim
day
age
initi
vaccin
calv
receiv
mlv
vaccinebacterin
combin
product
bovishield
gold
one
shot
zoeti
contain
mlv
strain
bvdv
type
brsv
mannheimia
haemolytica
multival
bacterintoxoid
product
vision
spur
merck
kenilworth
nj
intend
protect
anim
diseas
caus
clostridium
sp
moraxella
bovi
precondit
process
day
prior
wean
calv
day
old
calv
receiv
booster
respiratori
vaccin
bovishield
gold
one
shot
zoeti
anoth
multival
clostridi
vaccin
vision
merck
calv
wean
feedlot
day
age
note
time
studi
calv
receiv
bcv
contain
vaccin
timelin
sampl
collect
shown
fig
number
type
sampl
taken
time
point
summar
tabl
ml
blood
sampl
plasma
acquisit
collect
h
birth
small
subset
calv
birth
first
nurs
episod
observ
n
herd
herd
herd
ml
blood
sampl
serum
acquisit
nasal
swab
specimen
pathogen
detect
collect
studi
calv
n
initi
vaccin
precondit
wean
three
sampl
period
select
minim
stress
calv
excess
handl
calv
routin
process
vaccin
product
stage
usmarc
addit
ml
blood
sampl
nasal
swab
sampl
collect
calv
time
treatment
brd
studi
period
n
calv
sampl
treatment
blood
sampl
taken
via
jugular
venipunctur
use
needl
birth
initi
vaccin
needl
later
sampl
point
plasma
serum
separ
blood
compon
via
centrifug
x
g
min
store
nasal
sampl
collect
upper
nasal
caviti
calv
use
steril
cottontip
swab
sampl
nasal
swab
gentli
insert
nasal
caviti
approxim
depth
rotat
remov
nasal
swab
place
cryovial
contain
ml
transport
medium
buffer
pepton
water
glycerol
snap
frozen
liquid
nitrogen
store
two
subset
calv
herd
n
mass
treat
brd
august
accord
usmarc
standard
oper
procedur
sop
intervent
diseas
outbreak
fig
dam
prebreed
process
approxim
june
dam
calv
split
three
breed
group
base
dam
age
breed
group
separ
least
one
pastur
breed
group
share
fencelin
contact
time
august
calv
one
breed
group
n
studi
calv
mass
treat
brd
follow
observ
attend
veterinarian
approxim
calv
display
clinic
sign
brd
includ
cough
nasal
discharg
increas
respiratori
rate
lethargi
anorexia
calv
individu
restrain
squeez
chute
sampl
collect
describ
treatment
draxxin
tulathromycin
macrolid
zoeti
return
pastur
august
second
breed
group
n
studi
calv
mass
treat
differ
antibiot
zuprevo
tildipirosin
macrolid
merck
follow
observ
calv
pastur
display
clinic
sign
brd
similarli
sampl
treat
return
pastur
treatment
decis
made
attend
veterinarian
carri
accord
sop
multiplex
revers
transcript
realtim
polymeras
chain
reaction
rtqpcr
use
detect
bcv
brsv
bvdv
nasal
swab
sampl
previous
describ
use
primer
probe
set
previous
publish
report
briefli
rna
extract
sampl
use
phenol
guanidin
isothiocyan
reagent
trizol
ls
life
technolog
grand
island
ny
dna
extract
sampl
use
silicamembranebas
nucleic
acid
purif
kit
qiaamp
dna
mini
kit
qiagen
inc
valencia
ca
cyclic
amplif
reaction
carri
reaction
contain
mm
concentr
dntp
concentr
primer
concentr
probe
enzym
mix
contain
revers
transcriptas
rt
hot
start
taq
polymeras
onestep
rtpcr
kit
qiagen
inc
rna
dna
cycl
condit
follow
revers
transcript
min
inactiv
rt
enzym
activ
taq
polymeras
min
follow
cycl
ct
valu
consid
posit
posit
neg
templat
extract
control
includ
run
swab
taken
herd
calv
time
mass
treatment
brd
transport
medium
nasal
swab
sampl
pool
togeth
group
approxim
five
base
collect
date
calf
rectal
temperatur
time
treatment
pool
strategi
util
determin
whether
differ
preval
pathogen
calv
normal
rectal
temperatur
elev
rectal
temperatur
time
treatment
brd
rtqpcr
result
present
pool
sampl
subclin
shed
viral
pathogen
also
assess
rtqpcr
method
randomli
select
studi
calv
three
herd
initi
vaccin
precondit
wean
sampl
size
yield
probabl
detect
least
one
infect
anim
true
shed
preval
least
herd
product
stage
sampl
acquisit
time
transport
medium
nasal
swab
sampl
pool
togeth
group
five
base
origin
herd
sampl
pool
found
posit
viral
rna
dna
process
individu
identifi
posit
individu
pool
rtqpcr
result
report
number
individu
identifi
posit
test
individu
posit
pool
dna
extract
pool
nasal
swab
medium
sent
univers
nebraskalincoln
veterinari
diagnost
center
bacteri
diagnost
multiplex
qpcr
use
quantifast
multiplex
pcr
kit
qiagen
inc
primer
probe
design
detect
haemolytica
p
multocida
h
somni
mycoplasma
bovi
test
valid
use
bovin
nasal
swab
lung
tissu
matric
passiv
acquir
immun
bcv
matern
antibodi
evalu
subset
calv
herd
n
herd
herd
herd
measur
abund
serum
antibcv
igg
antibodi
calf
h
birth
bcv
antibodi
also
measur
calv
herd
evalu
bcv
shed
initi
vaccin
precondit
wean
addit
antibodi
level
measur
time
birth
wean
calv
herd
involv
mass
treatment
event
prewean
brd
august
antibodi
level
measur
use
commerci
avail
indirect
antibodi
elisa
bcv
antibodi
elisa
boehring
ingelheim
svanova
uppsala
sweden
accord
manufactur
instruct
previous
describ
briefli
optic
densiti
od
use
calcul
bcv
antibodi
percent
posit
divid
od
unknown
clinic
sampl
od
posit
control
provid
kit
per
manufactur
specif
percent
posit
valu
consid
seroneg
consid
seroposit
howev
goal
studi
compar
antibodi
abund
anim
herd
correl
valu
viru
shed
diseas
incid
first
experiment
determin
linear
rang
kit
good
linear
rang
od
demonstr
measur
valu
compar
expect
valu
linear
found
fit
follow
equat
x
sampl
od
dilut
retest
adjust
percent
posit
calcul
base
dilut
factor
clinic
sampl
time
percent
posit
valu
accept
rel
antibcv
antibodi
abund
kit
sensit
estim
specif
report
reduc
variat
kit
lot
number
use
test
microtitr
viru
neutral
test
vnt
use
determin
titer
neutral
antibcv
antibodi
subset
serum
plasma
sampl
n
goal
evalu
relationship
total
antibcv
reactiv
antibodi
measur
elisa
neutral
antibodi
titer
measur
vnt
test
cell
atcc
grown
maintain
mem
gibco
thermo
fisher
scientif
waltham
supplement
fetal
bovin
serum
atla
biolog
fort
collin
co
antibioticantimycot
gibco
mm
lglutamin
gibco
cell
seed
plate
cellswel
incub
day
cell
confluent
cell
wash
two
time
diluent
mem
supplement
antibioticantimycot
incub
h
ul
diluent
incub
serial
dilut
serumplasma
sampl
made
mem
separ
plate
use
duplic
row
sampl
challeng
viru
describ
dilut
mem
contain
tissu
cultur
infect
per
well
ad
serum
viru
serum
incub
one
hour
transfer
cell
plate
incub
incub
endpoint
titer
final
serumplasma
dilut
complet
inhibit
viral
cytopath
effect
well
sera
test
duplic
known
neg
control
sera
assay
two
challeng
strain
use
vnt
cell
cultur
adapt
us
refer
enter
strain
mebu
kindli
provid
dr
linda
saif
ohio
state
univers
columbu
oh
respiratori
strain
isol
naturallyinfect
calf
research
herd
serum
sampl
test
propag
six
time
cell
mebu
viru
strain
passag
multipl
cell
type
passag
number
unknown
total
bcvposit
nasal
swab
sampl
sequenc
directli
noncultur
clinic
sampl
six
herd
time
mass
treatment
eight
precondit
two
herd
four
herd
two
herd
one
wean
herd
prior
rna
extract
nasal
swab
treat
rnase
dnase
deplet
host
contamin
environment
nucleic
acid
previous
describ
remain
nucleic
acid
extract
use
trizol
ls
life
technolog
nest
pcr
use
amplifi
bp
fragment
spike
gene
includ
hypervari
region
use
phylogenet
analysi
coronaviru
stain
primer
bcv
forward
bcv
revers
nest
forward
nest
revers
sampl
final
pcr
product
run
agaros
gel
confirm
amplif
bp
product
fragment
purifi
remain
pcr
sampl
exonucleas
treatment
exo
life
technolog
grand
island
ny
accord
manufactur
specif
dna
precipit
ethanol
sequenc
twice
forward
direct
twice
revers
direct
use
nest
coronaviru
primer
commerci
sequenc
facil
genewiz
south
plainfield
nj
result
sequenc
data
analyz
edit
use
commerci
softwar
geneiou
version
biomatt
auckland
new
zealand
sequenc
align
carri
use
muscl
within
geneiou
singl
nucleotid
polymorph
snp
locat
determin
manual
comparison
bcv
strain
mebu
refer
genom
access
number
differ
wean
weight
wean
age
matern
bcv
igg
antibodi
log
across
herd
analyz
model
locat
fix
anim
residu
bacteri
preval
ye
outbreak
bacteri
abund
test
rel
bodi
temperatur
model
includ
mass
treatment
event
temperatur
statu
abovebelow
interact
due
binari
natur
preval
respons
variabl
logist
gener
model
fit
preval
chang
bcv
igg
serum
antibodi
level
log
time
model
repeat
measur
unstructur
multinomi
covari
residu
differ
time
point
locat
time
interact
test
fix
model
within
herd
two
brd
outbreak
occur
breed
group
fit
fix
rather
locat
track
differ
group
mass
treat
final
examin
relationship
bcv
shed
antibcv
igg
antibodi
level
differ
herd
igg
level
log
model
within
timepoint
fix
effect
locat
shed
statu
interact
anim
residu
pearson
correl
coeffici
deriv
describ
linear
relationship
result
obtain
vnt
elisa
vnt
use
mebu
brcv
challeng
strain
two
hundr
fortyeight
studi
clave
treat
brd
prior
wean
two
calv
herd
remain
case
herd
studi
calv
herd
treat
brd
comorbid
diarrhea
observ
brd
case
studi
calv
treat
diarrhea
point
studi
number
calv
treat
brd
inflat
herd
two
subset
calv
herd
sort
breed
group
time
base
dam
age
involv
outbreak
brd
lead
mass
treatment
calv
group
n
method
fig
time
first
mass
treatment
studi
calv
rectal
temperatur
threshold
indic
infecti
inflammatori
process
occur
calv
mean
age
calv
time
day
rang
day
calv
involv
second
mass
treatment
mean
age
day
rang
day
calv
rectal
temperatur
time
treatment
remain
case
herd
treat
outsid
time
mass
treatment
event
samplesrect
temperatur
obtain
five
case
third
breed
group
mass
treat
brd
addit
file
molecular
diagnost
carri
nasal
swab
specimen
collect
herd
time
mass
treatment
detect
common
viral
bcv
bvdv
brsv
bacteri
haemolytica
p
multocida
h
somni
bovi
pathogen
associ
brd
bcv
detect
pool
nasal
swab
across
treatment
date
statist
signific
differ
rel
abund
determin
rtqpcr
cycl
threshold
ct
detect
treatment
date
rectal
temperatur
normal
rectal
temperatur
within
treatment
date
fig
respiratori
viral
pathogen
detect
opportunist
bacteri
pathogen
h
somni
haemolytica
p
multocida
detect
nasal
swab
calv
across
treatment
date
summar
fig
differ
preval
rel
abund
h
somni
haemolytica
two
treatment
date
differ
p
multocida
abund
p
within
treatment
date
statist
differ
rel
abund
bacteria
analyz
rectal
temperatur
bovi
detect
nasal
swab
specimen
given
bacteria
commens
found
upper
respiratori
tract
urt
clinic
normal
anim
sampl
collect
appar
healthi
control
outsid
treatment
group
interpret
result
challeng
therefor
presenc
bacteria
determin
two
week
three
week
outbreak
routin
precondit
process
untreat
previous
treat
calv
herd
help
determin
bacteria
may
associ
brd
outbreak
fig
interestingli
time
mass
treatment
h
somni
detect
pool
test
across
treatment
date
fig
precondit
evid
h
somni
recov
calv
previous
treat
brd
control
calv
herd
involv
mass
treatment
event
fig
furthermor
evid
h
somni
nasal
caviti
calv
initi
vaccin
prior
brd
outbreak
data
shown
haemolytica
p
multocida
also
detect
high
level
calv
treat
brd
howev
bacteria
also
detect
pool
precondit
clinic
normal
calv
previous
treat
brd
fig
howev
statist
signific
increas
p
abund
p
multocida
upper
respiratori
tract
cattl
time
compar
untreat
group
precondit
process
data
shown
unsurprisingli
system
antibiot
therapi
calv
like
alter
bacteri
profil
upper
respiratori
tract
treat
anim
evidenc
reduc
preval
fig
abund
fig
bacteria
urt
precondit
compar
untreat
control
serum
antibcv
igg
antibodi
measur
elisa
sampl
collect
birth
wean
calv
herd
involv
mass
treatment
brd
august
order
determin
mean
antibodi
abund
rang
sampl
acquisit
time
fig
mean
standard
deviat
antibcv
antibodi
abund
declin
maximum
birth
low
time
mass
treatment
mean
antibodi
abund
increas
slightli
follow
mass
treatment
mean
antibodi
abund
precondit
wean
respect
neutral
antibodi
titer
measur
sampl
randomli
select
calv
determin
relationship
total
antibcv
reactiv
antibodi
measur
elisa
neutral
antibodi
titer
measur
viru
neutral
test
vnt
effect
alter
strain
test
viru
use
vnt
also
evalu
high
posit
mean
correl
observ
elisa
vnt
assay
regardless
test
viru
use
pearson
rank
correl
strain
mebu
strain
indic
good
excel
agreement
two
test
condit
addit
file
thu
elisa
use
subsequ
measur
antibcv
antibodi
determin
whether
level
passiv
acquir
matern
antibodi
associ
prewean
brd
incid
rel
antibcv
antibodi
abund
measur
subset
calv
herd
h
birth
herd
mean
sd
antibodi
abund
respect
thu
herd
highest
mean
level
passiv
acquir
antibcv
antibodi
also
largest
rang
antibodi
titer
fig
antibcv
serum
antibodi
level
also
measur
time
randomli
select
studi
calv
herd
initi
vaccin
precondit
wean
calv
evalu
herd
highest
mean
antibodi
abund
initi
vaccin
significantli
greater
herd
differ
herd
precondit
herd
highest
mean
antibodi
abund
significantli
greater
herd
herd
continu
highest
mean
antibodi
abund
wean
significantli
greater
herd
fig
determin
whether
antibcv
antibodi
level
predict
individu
herd
would
develop
sign
respiratori
diseas
antibodi
level
fig
replot
compar
mean
antibodi
abund
mass
treat
brd
rectal
temperatur
b
mass
treat
brd
rectal
temperatur
c
herd
remain
untreat
brd
throughout
studi
statist
signific
differ
mean
antibodi
abund
observ
within
sampl
acquisit
time
three
group
p
fig
summari
bcv
antibodi
abund
associ
prewean
brd
incid
within
herd
evalu
pathogen
exposur
subclin
respiratori
shed
bcv
well
brsv
bvdv
measur
randomli
select
calv
herd
evalu
antibcv
antibodi
level
initi
vaccin
precondit
wean
bovin
viral
diarrhea
viru
brsv
detect
calf
sampl
acquisit
time
bovin
coronaviru
detect
nasal
secret
two
two
calv
herd
respect
precondit
one
calf
herd
wean
tabl
thu
bcv
detect
three
herd
shed
highest
precondit
process
overal
preval
across
herd
randomli
select
calv
herd
involv
one
mass
treatment
event
brd
seven
calv
previous
treat
brd
shed
bcv
precondit
similarli
three
previous
treat
brd
shed
bcv
precondit
one
calf
shed
bcv
wean
treat
previous
brd
determin
serum
antibcv
antibodi
level
relat
respiratori
bcv
shed
antibcv
antibodi
level
fig
replot
compar
antibodi
level
found
shed
bcv
prewean
period
within
herd
clave
found
shed
bcv
mass
treatment
precondit
wean
significantli
differ
rel
antibcv
antibodi
abund
compar
rest
herd
measur
initi
vaccin
prior
shed
bcv
precondit
fig
wean
trend
herd
calv
shed
bcv
precondit
among
highest
antibcv
antibodi
abund
howev
sampl
size
extrem
small
n
therefor
statist
signific
differ
mean
antibodi
abund
found
shed
bcv
shed
bcv
product
stage
compar
bcv
strain
circul
three
herd
fragment
bcv
spike
gene
span
hypervari
domain
antigen
domain
ii
analyz
fifteen
posit
nasal
swab
analyz
six
herd
time
mass
treatment
two
four
eight
precondit
two
herd
four
herd
two
herd
one
wean
herd
total
four
snp
compar
consensu
identifi
three
sampl
lead
chang
predict
amino
acid
posit
tabl
first
three
amino
acid
chang
locat
within
hypervari
domain
last
two
locat
antigen
domain
ii
partial
overlap
hypervari
region
bcv
strain
two
anim
herd
sequenc
two
differ
sampl
acquisit
time
bcv
strain
infect
anim
differ
singl
nucleotid
two
time
point
contrast
bcv
strain
infect
anim
ident
locat
collect
point
furthermor
strain
present
herd
ident
strain
herd
compar
region
one
two
snp
present
strain
circul
herd
thu
strain
present
three
herd
similar
analyz
hypervari
region
spike
gene
anim
persist
infect
reinfect
similar
strain
cours
studi
studi
repres
first
prospect
longitudin
studi
relationship
antibcv
antibodi
level
bcv
infect
respiratori
diseas
nurs
beef
calv
two
outbreak
respiratori
diseas
one
research
herd
result
twothird
calv
mass
treat
brd
bcv
shed
found
occur
conjunct
prewean
brd
outbreak
howev
level
passiv
activ
acquir
immun
bcv
measur
found
associ
respiratori
diseas
incid
three
studi
herd
develop
brd
individu
calv
within
herd
rather
bcv
infect
like
common
mani
subclin
persist
recurr
infect
detect
result
studi
agre
result
previou
studi
young
dairi
calv
studi
dairi
calv
shed
viru
sometim
repeatedli
spite
rel
high
antibcv
antibodi
titer
furthermor
observ
statist
signific
correl
matern
bcv
specif
igg
serum
antibodi
titer
clinic
diseas
infect
bcv
popul
similarli
studi
report
found
bcv
specif
serum
igg
correl
respiratori
diseas
calv
herd
involv
mass
treatment
found
shed
bcv
two
sampl
acquisit
time
result
support
idea
persist
recurr
shed
episod
occur
anim
without
sign
diseas
bcv
infect
measur
viru
shed
similarli
found
associ
antibcv
antibodi
level
howev
measur
hamper
infrequ
sampl
collect
studi
design
fig
exampl
nearli
anim
herd
mass
treatment
group
shed
bcv
routin
sampl
collect
time
see
differ
antibcv
antibodi
abund
herd
calv
mass
treat
brd
herd
remain
untreat
possibl
even
like
mani
untreat
calv
also
shed
bcv
sampl
acquisit
date
lack
bcv
detect
nasal
swab
routin
collect
time
may
lead
fals
neg
bcv
infect
mask
influenc
antibodi
may
viru
shed
furthermor
small
number
bcv
posit
individu
found
herd
two
calv
herd
shed
bcv
precondit
process
hinder
abil
detect
confid
differ
may
exist
intens
sampl
would
requir
better
determin
associ
antibcv
antibodi
titer
bcv
infect
hypothet
reason
serum
antibcv
igg
abund
found
associ
bcv
infect
treatment
diseas
discuss
previous
among
lack
knowledg
relat
immun
correl
protect
respiratori
bcv
infect
cell
mediat
immun
antibodi
isotyp
iga
contribut
protect
infect
diseas
area
requir
addit
research
given
bcv
infect
common
remain
unknown
anim
display
sign
respiratori
diseas
other
remain
subclin
infect
determin
whether
differ
bcv
strain
circul
three
herd
nucleotid
fragment
spike
gene
analyz
spike
gene
encod
surfac
glycoprotein
respons
attach
host
cell
major
neutral
antigen
target
host
immun
system
region
spike
gene
span
hypervari
region
antigen
domain
ii
select
variabl
coronaviru
strain
isol
variat
region
associ
alter
antigen
andor
pathogen
speci
polymorph
found
region
herd
herd
isol
subclin
shed
episod
compar
isol
circul
time
brd
outbreak
furthermor
one
two
snp
found
isol
circul
herd
compar
isol
herd
contrast
snp
amino
acid
differ
detect
region
isol
compar
isol
collect
usmarc
univers
nebraskalincoln
veterinari
diagnost
center
unpublish
data
thu
differ
bcv
strain
circul
three
herd
unlik
account
major
differ
treatment
rate
observ
studi
one
side
effect
respiratori
viral
infect
increas
risk
bacteri
superinfect
bcv
may
occasion
produc
clinic
syndrom
consist
brd
absenc
bacteri
infect
involv
like
respiratori
virus
gener
consid
precursor
bacteri
infect
exacerb
diseas
thu
presenc
cosecondari
bacteri
infect
may
help
explain
differ
diseas
sever
bcvinfect
calv
observ
studi
use
qpcr
look
common
bacteri
pathogen
associ
respiratori
diseas
cattl
observ
h
somni
high
frequenc
abund
upper
respiratori
tract
sick
cattl
clinic
normal
cattl
herd
collect
week
outbreak
furthermor
h
somni
detect
calv
initi
vaccin
prior
diseas
outbreak
thu
hypothes
potenti
secondari
bacteri
infect
h
somni
may
explain
cattl
herd
display
sign
respiratori
diseas
subsequ
requir
treatment
note
howev
within
treatment
group
differ
rel
abund
h
somni
nasal
caviti
anim
categor
rectal
temperatur
taken
time
sampl
collect
treatment
suggest
infect
widespread
herd
though
anim
display
clinic
sign
diseas
particular
time
frequenc
differ
variou
strain
bacteria
differ
propens
caus
diseas
may
present
popul
differenti
assay
use
also
possibl
addit
pathogen
measur
studi
could
contribut
diseas
outbreak
thu
unbias
metagenom
approach
current
underway
determin
whether
addit
viral
bacteri
pathogen
associ
diseas
outbreak
urt
microbiom
may
influenc
respiratori
health
also
examin
popul
codetect
bcv
h
somni
time
diseas
outbreak
suggest
two
pathogen
contribut
diseas
pathogenesi
character
factor
may
contribut
outbreak
describ
help
veterinarian
research
produc
better
understand
risk
factor
associ
prewean
brd
inform
use
guid
prevent
control
strategi
decreas
incid
brd
associ
advers
anim
health
issu
product
loss
